80% Patient Activation: What Drives It (and What Kills It)

The single most important driver of passive monitoring outcomes is not the technology — it's the activation rate. If patients don't install EmoDTx, no data flows. No alerts fire. No revenue is protected.

Across our deployments, we've seen a consistent pattern: when a clinician proposes EmoDTx and installs it with the patient during the visit, 80% of patients activate within 48 hours. When the ask comes later by email or portal message, the rate drops to 30–40% — identical to PHQ-9 completion rates.

The conversation that drives activation

The physician conversation doesn't have to be long. The most effective version takes about 90 seconds:

"I want to monitor how you're doing between visits. There's an app called EmoDTx — you install it once in about three minutes, and then you don't have to do anything. It passively monitors your mood using your phone's sensors. I'll be able to see a trend of how you're doing every day, not just when I see you. It's helped me catch a few patients before they had a serious relapse. Would you be okay trying it?"

Three elements drive the 80%: the clinician proposing and installing it in the visit (social proof from someone the patient trusts), the framing as passive (no ongoing patient burden), and the concrete benefit (earlier intervention).

What kills activation

Four things reliably reduce activation rates: sending the install link by email rather than showing it in-clinic, asking during a busy clinical moment rather than a dedicated moment, using technical language ("multimodal AI biomarkers" rather than "monitors your mood"), and not explaining the why ("I'd like you to download this" without the benefit framing).

The operational implication

The highest-ROI thing you can do after deploying Emobot is train your clinical team on the activation conversation. It's not a technology problem — it's a communication one. And it's solvable in one 20-minute staff meeting.